"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial of a DNA vaccine in low grade B cell follicular lymphoma (LIFTT)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was looking at a
Low grade NHL usually responds well to treatment and can be kept under control for years. But it is not usually completely cured.
Researchers want to find out if cancer vaccines might help to treat NHL. This trial was very early research into having a DNA vaccine. The aims of the trial were to
- See if the immune system responded to the vaccine
- Find the best dose of the vaccine
- Learn more about the side effects
Summary of results
The trial team found that people with follicular lymphoma can have an
The trial recruited 25 people. The first 5 people who took part had the lowest dose of the vaccine. As they didn’t have any serious effects, the next 5 patients had a higher dose. And so on, until the trial team found the best dose to give. This is called a ‘
Ten people had a mild reaction at the injection site, but nobody had any serious side effects at any dose in this study. Nearly three quarters of the people taking part had an immune response to the vaccine.
We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Professor Robert Hawkins
Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
This is Cancer Research UK trial number CRUKD/99/016.